The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. (November 2015)

• Record Type: Journal Article
• Authors: Brown, Michael P; Bezak, Eva; Allen, Barry J
• Is Part Of: Melanoma management. Volume 2:Number 4(2015)
• Page Start: 353
• Page End: 366
• Publication Date: 2015-11
• Subjects: Bi-213 alpha emitter -- complementary therapies -- immunotherapy -- intralesional -- kinase inhibitors -- metastatic melanoma -- Phase I clinical trials -- radioisotopes -- systemic -- targeted alpha therapy; Melanoma -- Periodicals; 616.99477005
• DOI: 10.2217/mmt.15.26
• Languages: English
• ISSNs: 2045-0885

Abstract

Standard treatments for metastatic melanoma have recently extended survival although many patients still succumb. Targeted alpha therapy (TAT) is a new therapeutic approach in which a cancer-targeting vector is labeled with an alpha-emitting radioisotope. Alpha-particles have the shortest range and highest energy transfer, and produce localized, high-density and lethal ionization damage to DNA. Thus, the targeted radiation can kill isolated cancer cells circulating in blood and lymphatic vessels, regress metastatic cancer cell clusters, and disrupt the vasculature of solid tumors. Preclinical and clinical studies of TAT for metastatic melanoma demonstrate its safety and anti-tumor activity. We recommend ways in which TAT can be used to treat small-volume disease sometimes in conjunction with cytoreductive anti-melanoma therapies.